Testosterone News and Research

Latest Testosterone News and Research

Prevention, awareness of enlarged prostate can help save lives

We live in a country of excess where size often matters most. Supersize, grande, max, king size - but is bigger always better? Certainly not when it comes to male health and an enlarged prostate.

16 Jun 2010

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

Columbia Laboratories, Inc. today announced it completed enrollment in the PREGNANT (PROCHIEVE Extending GestatioN A New Therapy) Study last week. This randomized, double-blind, placebo controlled Phase III clinical study is evaluating the safety and efficacy of PROCHIEVE® 8% (progesterone gel) to reduce the risk of preterm birth in women with a cervical length between 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy.

8 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

Testosterone deficiency can lead to multiple disorders

Almost a quarter of men treated for cancer in their childhood suffer from a deficiency of the male sex hormone testosterone.

3 Jun 2010

Brain's cardiovascular, hormonal and asymmetric activation response when we get angry: UV scientists

When we get angry, the heart rate, arterial tension and testosterone production increases, cortisol (the stress hormone) decreases, and the left hemisphere of the brain becomes more stimulated. This is indicated by a new investigation lead by scientists from the University of Valencia that analyses the changes in the brain's cardiovascular, hormonal and asymmetric activation response when we get angry.

31 May 2010

VIVUS first-quarter 2010 total revenues decline: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring VIVUS Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

28 May 2010

Abnormal androgen signaling in ovaries cause female infertility

Male sex hormones, such as testosterone, have well defined roles in male reproduction and prostate cancer. What may surprise many is that they also play an important role in female fertility. A new study finds that the presence and activity of male sex hormones in the ovaries helps regulate female fertility, likely by controlling follicle growth and development and preventing deterioration of follicles that contain growing eggs.

27 May 2010

REDUCE trial data published in the online version of European Urology

On 8 May an editorial about the Reduction by Dutasteride of Prostate Cancer Events trial by Fritz H. Schröder and Monique J. Roobol was published in the online version of European Urology, the scientific journal of the European Association of Urology.

25 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

Choir singing induces state of stimulated regeneration in IBS patients

A Swedish investigation has compared choir singing and group discussion in irritable bowel syndrome in the current issue of Psychotherapy and Psychosomatics.

19 May 2010

Columbia Laboratories renews license and supply agreement with Merck Serono

Columbia Laboratories, Inc. has renewed its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE (progesterone gel) for an additional five-year term. Under the existing agreement and the renewal, Merck Serono has marketing rights worldwide, except the United States.

18 May 2010

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.

18 May 2010

Low testosterone levels can impact sleep quality

At 30 years old, male testosterone levels drop by one to two percent annually. By age 40, men's quality of sleep begins to diminish. Could there be a link between decreased testosterone and reduced sleep?

15 May 2010

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

BioSante Pharmaceuticals, Inc. today reported on its recent developments and financial results for the first quarter, and its cash balance as of March 31, 2010.

14 May 2010

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.

14 May 2010

Columbia Laboratories reports 34% increase in net revenues from U.S. sales of progesterone products

Columbia Laboratories, Inc. today announced financial results for the three-month period ended March 31, 2010.

6 May 2010

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

CPEX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010. For the quarter CPEX reported revenues of $5.3 million and a net loss of $940,000.

5 May 2010

Australian researchers show positive effect of growth hormone on athletic performance

Australian researchers have published the results of a study, for the first time showing a positive effect of growth hormone on athletic performance.

5 May 2010

HGH improves athletic performance: Study

A study released today in Annals of Internal Medicine, the flagship journal of the American College of Physicians, finds that human growth hormone improves sprint capacity in healthy recreational athletes. This is the first trial to demonstrate that HGH improves athletic performance.

4 May 2010

Testosterone News and Research

Latest Testosterone News and Research

Prevention, awareness of enlarged prostate can help save lives

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

Testosterone deficiency can lead to multiple disorders

Brain's cardiovascular, hormonal and asymmetric activation response when we get angry: UV scientists

VIVUS first-quarter 2010 total revenues decline: MicroStockProfit.com

Abnormal androgen signaling in ovaries cause female infertility

REDUCE trial data published in the online version of European Urology

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

Choir singing induces state of stimulated regeneration in IBS patients

Columbia Laboratories renews license and supply agreement with Merck Serono

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Low testosterone levels can impact sleep quality

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Columbia Laboratories reports 34% increase in net revenues from U.S. sales of progesterone products

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

Australian researchers show positive effect of growth hormone on athletic performance

HGH improves athletic performance: Study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Testosterone News and Research

Latest Testosterone News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in